GSK’s Bepirovirsen Gets Green Light for EMA Review, Paving Way for Potential Approval in Europe
GSK’s bepirovirsen, a potential treatment for chronic hepatitis B, has been accepted for review by the European Medicines Agency (EMA), marking a significant step towards potential approval in Europe and bringing hope to millions of people affected by the disease worldwide.
Read More